These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 29986181)

  • 1. Structural comparison of Mtb-DHFR and h-DHFR for design, synthesis and evaluation of selective non-pteridine analogues as antitubercular agents.
    Sharma K; Tanwar O; Sharma S; Ali S; Alam MM; Zaman MS; Akhter M
    Bioorg Chem; 2018 Oct; 80():319-333. PubMed ID: 29986181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of novel selective Mtb-DHFR inhibitors as antitubercular agents through structure-based computational techniques.
    Sharma K; Neshat N; Sharma S; Giri N; Srivastava A; Almalki F; Saifullah K; Alam MM; Shaquiquzzaman M; Akhter M
    Arch Pharm (Weinheim); 2020 Feb; 353(2):e1900287. PubMed ID: 31867798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expansion of a novel lead targeting M. tuberculosis DHFR as antitubercular agents.
    Sharma K; Tanwar O; Deora GS; Ali S; Alam MM; Zaman MS; Krishna VS; Sriram D; Akhter M
    Bioorg Med Chem; 2019 Apr; 27(7):1421-1429. PubMed ID: 30827867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The identification of novel Mycobacterium tuberculosis DHFR inhibitors and the investigation of their binding preferences by using molecular modelling.
    Hong W; Wang Y; Chang Z; Yang Y; Pu J; Sun T; Kaur S; Sacchettini JC; Jung H; Lin Wong W; Fah Yap L; Fong Ngeow Y; Paterson IC; Wang H
    Sci Rep; 2015 Oct; 5():15328. PubMed ID: 26471125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation, biological evaluation and molecular docking study of imidazolyl dihydropyrimidines as potential Mycobacterium tuberculosis dihydrofolate reductase inhibitors.
    Desai NC; Trivedi AR; Khedkar VM
    Bioorg Med Chem Lett; 2016 Aug; 26(16):4030-5. PubMed ID: 27397497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragment Discovery for the Design of Nitrogen Heterocycles as Mycobacterium tuberculosis Dihydrofolate Reductase Inhibitors.
    Shelke RU; Degani MS; Raju A; Ray MK; Rajan MG
    Arch Pharm (Weinheim); 2016 Aug; 349(8):602-13. PubMed ID: 27320965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shape-based virtual screening, docking, and molecular dynamics simulations to identify Mtb-ASADH inhibitors.
    Kumar R; Garg P; Bharatam PV
    J Biomol Struct Dyn; 2015; 33(5):1082-93. PubMed ID: 24875451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docking- and pharmacophore-based virtual screening for the identification of novel Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) inhibitor with a thiobarbiturate scaffold.
    Zhang D; Lin Y; Chen X; Zhao W; Chen D; Gao M; Wang Q; Wang B; Huang H; Lu Y; Lu Y
    Bioorg Chem; 2019 Apr; 85():229-239. PubMed ID: 30641319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase.
    Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of 9H-fluorenone based 1,2,3-triazole analogues as Mycobacterium tuberculosis InhA inhibitors.
    Suresh A; Srinivasarao S; Agnieszka N; Ewa AK; Alvala M; Lherbet C; Chandra Sekhar KVG
    Chem Biol Drug Des; 2018 Jun; 91(6):1078-1086. PubMed ID: 29063733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs.
    Li R; Sirawaraporn R; Chitnumsub P; Sirawaraporn W; Wooden J; Athappilly F; Turley S; Hol WG
    J Mol Biol; 2000 Jan; 295(2):307-23. PubMed ID: 10623528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tryptanthrin Analogues as Inhibitors of Enoyl-acyl Carrier Protein Reductase: Activity against Mycobacterium tuberculosis, Toxicity, Modeling of Enzyme Binding.
    Duca G; Pogrebnoi S; Boldescu V; Aksakal F; Uncu A; Valica V; Uncu L; Negres S; Nicolescu F; Macaev F
    Curr Top Med Chem; 2019; 19(8):609-619. PubMed ID: 30834838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virtual screening and synthesis of novel antitubercular agents through interaction-based pharmacophore and molecular docking studies.
    Bhattarai D; Muddassar M; Jang JW; Hong SK; Kim EE; Oh T; Cho SN; Pae AN; Keum G
    Curr Comput Aided Drug Des; 2014; 10(4):383-92. PubMed ID: 25872944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and development of 2-methylimidazo[1,2-a]pyridine-3-carboxamides as Mycobacterium tuberculosis pantothenate synthetase inhibitors.
    Samala G; Nallangi R; Devi PB; Saxena S; Yadav R; Sridevi JP; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2014 Aug; 22(15):4223-32. PubMed ID: 24953948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and structure activity relationships of cyanopyridone based anti-tuberculosis agents.
    Jian Y; Hulpia F; Risseeuw MDP; Forbes HE; Munier-Lehmann H; Caljon G; Boshoff HIM; Van Calenbergh S
    Eur J Med Chem; 2020 Sep; 201():112450. PubMed ID: 32623208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bis-spirochromanones as potent inhibitors of Mycobacterium tuberculosis: synthesis and biological evaluation.
    Dongamanti A; Aamate VK; Devulapally MG; Gundu S; Balabadra S; Manga V; Yogeeswari P; Sriram D; Balasubramanian S
    Mol Divers; 2017 Nov; 21(4):999-1010. PubMed ID: 28840414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-based design, synthesis and preliminary evaluation of selective inhibitors of dihydrofolate reductase from Mycobacterium tuberculosis.
    El-Hamamsy MH; Smith AW; Thompson AS; Threadgill MD
    Bioorg Med Chem; 2007 Jul; 15(13):4552-76. PubMed ID: 17451962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and evaluation of substituted nicotinamide adenine dinucleotide (NAD
    Wang X; Ahn YM; Lentscher AG; Lister JS; Brothers RC; Kneen MM; Gerratana B; Boshoff HI; Dowd CS
    Bioorg Med Chem Lett; 2017 Sep; 27(18):4426-4430. PubMed ID: 28827112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
    Kumar S; Mehra R; Sharma S; Bokolia NP; Raina D; Nargotra A; Singh PP; Khan IA
    Tuberculosis (Edinb); 2018 Jan; 108():56-63. PubMed ID: 29523328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Insights into Mycobacterium tuberculosis Rv2671 Protein as a Dihydrofolate Reductase Functional Analogue Contributing to para-Aminosalicylic Acid Resistance.
    Cheng YS; Sacchettini JC
    Biochemistry; 2016 Feb; 55(7):1107-19. PubMed ID: 26848874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.